Alnylam to Host Conference Call to Discuss Collaboration with Novartis to Develop RNAi Therapeutics for Pandemic Flu.CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), announced today that the company will hold a conference call on Tuesday, February 21, 2006 at 9:00 a.m. ET. During the call, Alnylam will discuss its newly formed collaboration with Novartis to develop an RNAi therapeutic for pandemic flu. Conference Call Information The call may be accessed by dialing 800-706-7745 (domestic) or 617-614-3472 (international) five minutes prior to the start time, and providing the passcode 90344687. A replay of the call will be available from 11:00 a.m. ET on February 21, 2006 until February 27, 2006. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 34942874. A live audio webcast of the call will also be available on the "Investors" section of the Company's website, http://www.alnylam.com. An archived webcast will be available on the Alnylam website approximately two hours after the event, and will be archived for 14 days thereafter. About Alnylam Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus respiratory syncytial syncytial /syn·cy·tial/ (sin-sish´al) of or pertaining to a syncytium. virus n. Abbr. RSV (RSV) infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach Kulmbach, town (1994 pop. 28,260), Bavaria, central Germany, on the White Main River. Known in 1035, Kulmbach became (1340) the residence of the margraves of Kulmbach (later known as the margraves of Bayreuth) of the house of Hohenzollern. In 1791 the town passed to Prussia, in 1807 it was taken by France, and in 1810 it was annexed by Bavaria and made part of Upper Franconia. On a nearby hill is the fortress (now a museum) of Plassenburg (12th cent., Germany. Alnylam is honored to be the 'emerging/mid-cap' company recipient of the 2006 James D. Watson Helix Award, the biotechnology industry's award for outstanding achievement. For more information, please visit www.alnylam.com.
An RNA-containing virus that causes minor respiratory infections in adults and bronchitis and bronchopneumonia in children. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion